Physician profile

Jong W Park

Family Medicine · Orange, CA

NPI 1497719942

$476.55

in general payments reported to CMS, 2019-2025

12 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$13.43

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $195.51 2019-2020
Glaxosmithkline, LLC. $48.42 2019-2022
Astellas Pharma US INC $37.50 2019
Astrazeneca Pharmaceuticals Lp $34.58 2019
Amgen INC. $32.86 2019-2023 Repatha, Otezla
Abbott Laboratories $24.08 2019
Medtronic Vascular, INC. $23.98 2019
Valeritas, INC. $23.22 2019
Pfizer INC. $20.53 2019
Lilly USA, LLC $12.93 2019
Sanofi Pasteur INC. $11.76 2019
Medtronic, INC. $11.18 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jong W Park

$476.55

in general payments reported 2019-2025

Years
2019-2023
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/294249/jong-w-park

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.